Neogen's $160M Genomics Sale: Smart Focus or a Margin Trade Too Risky?

The genomics sale simplifies Neogen, but it does not finish the turnaround

Neogen is selling its genomics unit for $160 million to shedding a business that still produced about $90 million in fiscal 2025 sales. Management says the net proceeds will be used primarily for debt reduction. That is straightforward capital allocation: remove a lower-priority unit, reduce leverage, and keep management focused on the parts of the business tied to food and animal safety.

The bull case is that the core still has enough substance to make the trade worthwhile. In the fourth quarter, Neogen posted core growth of 4.3%, Food Safety posted 5.8% core growth, and the quarter produced $30.2 million of cash flow from operations. If the remaining business can keep creating cash, getting rid of a weaker portfolio piece can be meaningful.

The bear case is that the core still needs more than a cleaner balance sheet. Reported revenue declined 0.1% in Q4, and the company recorded a net loss of $11.3 million. The timing risk matters too: the genomics sale is expected to close by the end of the first half of Neogen's 2027 fiscal year, and management says fiscal 2027 will still focus on strategic investments. So investors are being asked to underwrite a future balance-sheet improvement before the operating engine is fully fixed.

Food Safety looks useful; Animal Safety shows where the operating test still matters

The sale makes the story cleaner, but the real question is whether the remaining business is strong enough to deserve more investment.

Food Safety still looks like a real operating core

Food Safety appears to have practical stickiness. Neogen is helping customers turn monitoring data into risk-based decisions, which fits the idea of a company that is partner helping connect systems. That does not solve the whole valuation debate, but it suggests the core has a reason to stay in customers' workflows.

Animal Safety is the clearest operating test

In the third quarter, Animal Safety looked weak on the surface: revenue growth of (20.1%) and core growth of (8.7%), with management attributing the slowdown to third-party supplier challenges. That is easier to tolerate if the issue is execution, not demand.

The next quarter offered a better read. Animal Safety still posted revenue growth of (8.2%), but core growth improved to 0.5%, and revenue rose 7% sequentially as the majority of supply challenges resolved. That looks less like product fatigue and more like a recovery from distribution friction.

Profitability improved even while execution was catching up

The more reassuring signal is that profitability did not fall apart while the business was working through supply issues. In Q3, Neogen reported adjusted EBITDA margins of 22.8%, up 110 basis points sequentially. In Q4, the company generated adjusted EBITDA of $45.4 million and $30.2 million of cash flow from operations. That does not prove the turnaround is complete, but it does argue against the idea that the core is structurally broken.

What needs to happen next for the thesis to hold

If Animal Safety was hurt mainly by supply execution rather than fading customer loyalty, the sale starts to look more justified. The next real test is whether the Petrifilm manufacturing transition stays clean and whether management can keep its commercial focus through strategic investments. If those pieces hold, the divestiture likely simplifies the business. If not, the sale still helps the balance sheet, but it does not fully solve the operating story.

The key scorecard is leverage, while investors watch whether the core keeps improving

The near-term debate is less about slogans and more about whether the balance-sheet improvement shows up before interest in the story fades.

The first target is the debt ratio

Investors should lead with one measurable checkpoint: Neogen says the genomics sale's net cash proceeds should support net debt-to-adjusted EBITDA of less than three times by end of CY2026. That is the most decision-useful target in the disclosure because it can be tracked quarter by quarter. The deal is $160 million, and the timing leaves the next few quarters as the window where investors need to see progress on de-leveraging, not just hope for it later.

Bullish signals to watch

• The leverage ratio keeps moving toward the sub-3x target before closing, showing the proceeds are doing work now rather than only at closing.
• The core business stays steadier while management spends through strategic investments, suggesting focus is translating into execution.
• Operating health remains intact, with prior quarters showing core growth of 4.3% and $30.2 million of operating cash flow in Q4.

Bearish signals to watch

• Revenue headlines stay uneven even after the portfolio simplification is announced.
• The core continues to need support rather than showing durable strength on its own.
• The buyer is Zoetis, which makes the sale credible, but it does not remove the need for the remaining business to perform.

What would weaken the setup

Treat the thesis as weaker if the debt target slips beyond end-2026, if closing delays push the benefits too far out subject to regulatory approval and customary closing conditions, or if management starts using the proceeds for anything other than the stated debt-reduction purpose. The argument is simplest when the balance sheet gets cleaner and the core gets tougher, not just the story.